Jesus J Gomar1,2, Concepcion Conejero-Goldberg1, Peter Davies1,3, Terry E Goldberg1,3. 1. The Litwin-Zucker Research Center, Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, USA. 2. FIDMAG Hermanas Hospitalarias Research Foundation & CIBERSAM, Sant Boi de Llobregat, Spain. 3. Hofstra North Shore LIJ School of Medicine, Hempstead, NY, USA.
Abstract
BACKGROUND: The earliest stage of preclinical Alzheimer's disease (AD) is defined by low levels of cerebrospinal fluid (CSF) amyloid-β (Aβ42). However, covariance in longitudinal dynamic change of Aβ42 and tau in incipient preclinical AD is poorly understood. OBJECTIVE: To examine dynamic interrelationships between Aβ42 and tau in preclinical AD. METHODS: We followed 47 cognitively intact participants (CI) with available CSF data over four years in ADNI. Based on longitudinal Aβ42 levels in CSF, CI were classified into three groups: 1) Aβ42 stable with normal levels of Aβ42 over time (n = 15); 2) Aβ42 declining with normal Aβ42 levels at baseline but showing decline over time (n = 14); and 3) Aβ42 levels consistently abnormal (n = 18). RESULTS: In the Aβ42 declining group, suggestive of incipient preclinical AD, CSF phosphorylated tau (p-tau) showed a similar longitudinal pattern of increasing abnormality over time (p = 0.0001). Correlation between longitudinal slopes of Aβ42 and p-tau confirmed that both trajectories were anti-correlated (rho = -0.60; p = 0.02). Regression analysis showed that Aβ42 slope (decreasing Aβ42) predicted p-tau slope (increasing p-tau) (R2 = 0.47, p = 0.03). Atrophy in the hippocampus was predicted by the interaction of Aβ42 and p-tau slopes (p < 0.0001) only in this incipient preclinical AD group. In all groups combined, memory decline was predicted by p-tau. CONCLUSIONS: The evolution of Aβ42 and p-tau CSF biomarkers in CI subjects follows an anti-correlated trajectory, i.e., as Aβ42 declined, p-tau increased, and thus was suggestive of strong temporal coincidence. Rapid pathogenic cross-talk between Aβ42 and p-tau thus may be evident in very early stages of preclinical AD.
BACKGROUND: The earliest stage of preclinical Alzheimer's disease (AD) is defined by low levels of cerebrospinal fluid (CSF) amyloid-β (Aβ42). However, covariance in longitudinal dynamic change of Aβ42 and tau in incipient preclinical AD is poorly understood. OBJECTIVE: To examine dynamic interrelationships between Aβ42 and tau in preclinical AD. METHODS: We followed 47 cognitively intact participants (CI) with available CSF data over four years in ADNI. Based on longitudinal Aβ42 levels in CSF, CI were classified into three groups: 1) Aβ42 stable with normal levels of Aβ42 over time (n = 15); 2) Aβ42 declining with normal Aβ42 levels at baseline but showing decline over time (n = 14); and 3) Aβ42 levels consistently abnormal (n = 18). RESULTS: In the Aβ42 declining group, suggestive of incipient preclinical AD, CSF phosphorylated tau (p-tau) showed a similar longitudinal pattern of increasing abnormality over time (p = 0.0001). Correlation between longitudinal slopes of Aβ42 and p-tau confirmed that both trajectories were anti-correlated (rho = -0.60; p = 0.02). Regression analysis showed that Aβ42 slope (decreasing Aβ42) predicted p-tau slope (increasing p-tau) (R2 = 0.47, p = 0.03). Atrophy in the hippocampus was predicted by the interaction of Aβ42 and p-tau slopes (p < 0.0001) only in this incipient preclinical AD group. In all groups combined, memory decline was predicted by p-tau. CONCLUSIONS: The evolution of Aβ42 and p-tau CSF biomarkers in CI subjects follows an anti-correlated trajectory, i.e., as Aβ42 declined, p-tau increased, and thus was suggestive of strong temporal coincidence. Rapid pathogenic cross-talk between Aβ42 and p-tau thus may be evident in very early stages of preclinical AD.
Entities:
Keywords:
Aβ42; brain atrophy; cerebrospinal fluid; cognition; p-tau; preclinical AD
Authors: Julia A Scott; Meredith N Braskie; Duygu Tosun; Pauline Maillard; Paul M Thompson; Michael Weiner; Charles DeCarli; Owen T Carmichael Journal: Neurobiol Aging Date: 2016-08-24 Impact factor: 4.673
Authors: Christine L Tardif; Gabriel A Devenyi; Robert S C Amaral; Sandra Pelleieux; Judes Poirier; Pedro Rosa-Neto; John Breitner; M Mallar Chakravarty Journal: Hum Brain Mapp Date: 2017-11-21 Impact factor: 5.038
Authors: Reisa A Sperling; Elizabeth C Mormino; Aaron P Schultz; Rebecca A Betensky; Kathryn V Papp; Rebecca E Amariglio; Bernard J Hanseeuw; Rachel Buckley; Jasmeer Chhatwal; Trey Hedden; Gad A Marshall; Yakeel T Quiroz; Nancy J Donovan; Jonathan Jackson; Jennifer R Gatchel; Jennifer S Rabin; Heidi Jacobs; Hyun-Sik Yang; Michael Properzi; Dylan R Kirn; Dorene M Rentz; Keith A Johnson Journal: Ann Neurol Date: 2019-01-21 Impact factor: 10.422
Authors: Betty M Tijms; Lisa Vermunt; Marissa D Zwan; Argonde C van Harten; Wiesje M van der Flier; Charlotte E Teunissen; Philip Scheltens; Pieter Jelle Visser Journal: Ann Clin Transl Neurol Date: 2018-07-20 Impact factor: 4.511